The Lyon site, one of several Ricerca gained through the acquisition of MDS Pharma Services’ discovery and life sciences business in March, acts as a European hub for the firm’s drug safety assessment business.
CEO Ian Lennox said that: “As a recipient of this certification, our concern and thorough attention to our client needs are evident,” adding that “ensuring our discovery and development services meet the standards required of us.”
The award is the second the US contract research organisation (CRO) has received in the last 12 months, following the certification of its facility in Taiwan in October last year.